| Identification | Back Directory | [Name]
Fluasterone | [CAS]
112859-71-9 | [Synonyms]
fluasterone
16-fluoro-5-androsten-17-one
Androst-5-en-17-one, 16-fluoro-, (16α)-
(8R,9S,10R,13S,14S,16R)-16-fluoro-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one | [Molecular Formula]
C19H27FO | [MDL Number]
MFCD00874717 | [MOL File]
112859-71-9.mol | [Molecular Weight]
290.42 |
| Chemical Properties | Back Directory | [Melting point ]
165 - 168oC | [Boiling point ]
382.5±42.0 °C(Predicted) | [density ]
1.09±0.1 g/cm3(Predicted) | [storage temp. ]
Hygroscopic, -20°C Freezer, Under inert atmosphere | [solubility ]
Chloroform (Slightly), Methanol (Very Slightly, Heated) | [form ]
Solid | [color ]
White to Off-White |
| Hazard Information | Back Directory | [Uses]
A synthetic derivative of Dehydroepiandrosterone. The reduced androgenicity of Fluasterone may obviate toxicities associated with the androgenicity of the parent compound. Antitumor agent. Used in clinical trials for prostate cancer prevention. | [Uses]
Fluasterone is a synthetic derivative of Dehydroepiandrosterone. The reduced androgenicity of Fluasterone may obviate toxicities associated with the androgenicity of the parent compound. Antitumor agent. Fluasterone is used in clinical trials for prostate cancer prevention.
| [in vivo]
Fluasterone (0.2% and 0.3%; in diet for 39 days) shows anti-hyperglycemic effect in diabetic mice[2].
Fluasterone (200 μg/mouse; intradermal injection; once) suppresses the TPA-induced acute inflammatory and epidermal hyperplastic effect[3]. | Animal Model: | Male C57BL/KsJ db/db mice, diabetic model[2] | | Dosage: | 0.2% and 0.3% | | Administration: | In the diet for 39 days | | Result: | Markedly reduced plasma glucose levels. |
|
|
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
|